Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin in Platinum-Resistant Ovarian Cancer (CORAIL)
NCT02421588Phase 3Completed
- Sponsor
- PharmaMar
- Start
- May 2015
- Primary completion
- Oct 2018
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of lurbinectedin in ovarian cancer, sponsored by PharmaMar. Started May 2015; status: completed.
02
Drugs
lurbinectedin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02421588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02421588.